CoChat

The DOI matches its Crossref record; 94 of the 96 references it cites were found in a registry or an index; none of the 84 sources its claims cite is checked for support yet.

Microglial SIRT2 deficiency aggravates cognitive decline and amyloid pathology in Alzheimer’s disease

Open access
Sola-Sevilla, Noemi, Garmendia-Berges, Maider, Aleixo, Mikel, Mera-Delgado, MCarmen, Solas, Maite, Tordera, Rosa M., García-Carracedo, Lucía, Expósito, Sara, Anaya-Cubero, Elena, Fernández-Irigoyen, Joaquín, Guruceaga, Elisabeth, Santamaria, Enrique, Martin, Eduardo D., Puerta, Elena · 2025 · Brain, Behavior, and Immunity

Published version of a preprint

Abstract

Sirtuin 2 (SIRT2), a NAD+-dependent deacetylase, has been implicated in aging and neurodegenerative diseases such as Alzheimer's disease (AD). While global SIRT2 inhibition has shown promise in reducing amyloid-beta pathology and cognitive deficits in different mouse models of AD, peripheral SIRT2 inhibition has been associated with adverse effects, such as increased inflammation. This suggests that targeted inhibition of specific cellular populations within the brain may represent a more precise and effective approach for the treatment of AD. To explore this hypothesis, we generated a conditional microglial SIRT2 knockout mouse model in the context of AD. Our results reveal that microglial SIRT2 reduction does not confer protective effects in the APP/PS1 model; rather, it aggravates cognitive decline, accelerates amyloid plaque deposition, and increases levels of pro-inflammatory cytokines at early stages of AD pathology. Transcriptomic analysis further indicates that SIRT2-deficient microglia exhibit altered expression of genes associated with aging and synaptic dysfunction. This phenotype was accompanied by increased phagocytosis of PSD95 and impaired long-term potentiation. These findings suggest that while SIRT2 inhibition in some contexts may be beneficial, targeted inhibition within microglia could accelerate AD progression, underscoring the need for cell-specific approaches when considering SIRT2 as a therapeutic target.

Overview

CoChat Summary

TL;DR

Microglial SIRT2 deletion did not protect against Alzheimer’s disease in APP/PS1 mice; instead, it worsened early pathology, reducing survival, accelerating amyloid deposition and cognitive decline, and impairing synaptic plasticity. These findings argue that SIRT2 inhibition may need cell-specific targeting, because microglial SIRT2 loss can be detrimental.

Key findings

  • In 8-month-old APP/PS1 mice, microglial SIRT2 deficiency did not improve cognition or amyloid pathology: no significant differences were found in Aβ plaque burden, average plaque size, or plaque number between APP/PS1 and APP/PS1-SIRT2ΔTmem119 mice.
  • In 5-month-old APP/PS1 mice, microglial SIRT2 deficiency reduced survival (48.3% vs 63% survival at 25 weeks), worsened learning/memory in the Morris water maze, and accelerated amyloid pathology (increased 6E10 staining, larger average plaque size, elevated Aβ1-42, and increased Il-1β and Il-6). Microglial coverage of plaques smaller than 50 μm was decreased.
  • Bulk RNA sequencing of hippocampal microglia showed 526 differentially expressed genes in SIRT2ΔTmem119 vs control (200 up-regulated, 326 down-regulated); 652 genes changed between APP/PS1-SIRT2ΔTmem119 and SIRT2ΔTmem119 vs 251 between control and APP/PS1. Aging- and AD-associated gene sets were enriched, with no consistent overlap with the disease-associated microglia signature.
  • SIRT2ΔTmem119 and APP/PS1-SIRT2ΔTmem119 mice showed reduced c-Fos+ cells in the dentate gyrus and substantially reduced hippocampal LTP. SIRT2ΔTmem119 microglia had increased PSD95 engulfment and reduced total PSD95, while VGLUT1 was unchanged.

Methods

  • Conditional microglial SIRT2 knockout mice (Sirt2 flx/flx-Tmem119 cre/ERT2) were crossed with APP/PS1 mice; tamoxifen (100 mg/kg i.p. every 24 h for 5 days) was administered at 6 and 10 weeks of age, and both sexes were pooled after preliminary evaluations showed no sex-specific trends.
  • Behavioral tests (open field, elevated plus maze, marble burying, forced swim, Morris water maze), electrophysiology (LTP), microglia isolation/MACS, flow cytometry, bulk RNA sequencing, qPCR, Western blot, Golgi staining, immunofluorescence, and Aβ1-42 ELISA were performed at 5 and 8 months.
  • Differential expression was analyzed with edgeR/voom/LIMMA, followed by GO, GSEA, and Metascape; RNA-seq data are in GEO (GSE280235). Statistics used two-way ANOVA with Tukey’s post hoc, repeated-measures two-way ANOVA, t tests/Mann-Whitney U, and Log-rank tests as appropriate.

Limitations

  • The paper states that further studies using animal models with more pronounced tau pathology are needed to confirm the lack of detectable tau phosphorylation impact, and that mechanisms underlying LTP impairment remain unclear and warrant further investigation; the exosome hypothesis also requires further characterization.
  • Evident from the text: conclusions rely on a single APP/PS1 mouse model and bulk microglial RNA sequencing, with no human data or single-cell resolution; both sexes were pooled after preliminary evaluations showed no sex-specific trends.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/j.bbi.2025.06.016

Cites

94 of 94 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Image 1
CC-BY · From the PDF
(caption on next page)
(caption on next page)CC-BY · From the PDF
Image 3
CC-BY · From the PDF
Image 4
CC-BY · From the PDF
(caption on next page)
(caption on next page)CC-BY · From the PDF
Fig. 5 SIRT2 deficient microglia exhibit alterations in the expression of genes associated with aging and neuronal activity. (A) Five-month-old mice were sacrificed and microglia from the hippocampus were isolated to perform bulk RNA sequencing. (B) GO Biological Processes with the highest significant fold enrichment when control and SIRT2 Δ Tmem119 groups were compared. (C-E) Gene Set Enrichment Analysis (GSEA) indicating a repression of genes related to synaptic interaction (C) , neuronal system (D) and neurotransmitter release (E) in SIRT2 Δ Tmem119 microglia. (F) Heatmap showing the most downregulated genes associated with synapses in SIRT2 Δ Tmem119 microglia. (G-I) Gene Set Enrichment Analysis (GSEA) indicating an upregulation of genes related to aging (G) and Alzheimer ' s disease (H-I) in SIRT2 Δ Tmem119 microglia. (J) Heatmap showing the most upregulated genes associated with aging and Alzheimer ' s disease (AD) in SIRT2 Δ Tmem119 microglia (n = 4 animals/group).
Fig. 5 SIRT2 deficient microglia exhibit alterations in the expression of genes associated with aging and neuronal activity. (A) Five-month-old mice were sacrificed and microglia from the hippocampus were isolated to perform bulk RNA sequencing. (B) GO Biological Processes with the highest significant fold enrichment when control and SIRT2 Δ Tmem119 groups were compared. (C-E) Gene Set Enrichment Analysis (GSEA) indicating a repression of genes related to synaptic interaction (C) , neuronal system (D) and neurotransmitter release (E) in SIRT2 Δ Tmem119 microglia. (F) Heatmap showing the most downregulated genes associated with synapses in SIRT2 Δ Tmem119 microglia. (G-I) Gene Set Enrichment Analysis (GSEA) indicating an upregulation of genes related to aging (G) and Alzheimer ' s disease (H-I) in SIRT2 Δ Tmem119 microglia. (J) Heatmap showing the most upregulated genes associated with aging and Alzheimer ' s disease (AD) in SIRT2 Δ Tmem119 microglia (n = 4 animals/group).CC-BY · From the PDF
Fig. 6 Microglial deficiency of SIRT2 modifies the transcriptome in the context of Alzheimer ' s disease pathology. (A) Venn diagram illustrating the comparison of differentially expressed genes between APP/PS1 versus Control microglia and APP/PS1-SIRT2 Δ Tmem119 versus SIRT2 Δ Tmem119 microglia. Overlapping areas represent shared genes between the two comparisons, while non-overlapping regions indicate genes specific to each group. (B) Heatmap of the Gene Ontology (GO) functional analysis of differentially expressed genes in the comparisons APP/PS1 versus Control microglia and APP/PS1 versus APP/PS1-SIRT2 Δ Tmem119 microglia. Color intensity represents the statistical significance ( log10 p-value) of each enriched GO term. (C) Top 20 GO Biological Processes altered in the comparison between APP/PS1-SIRT2 Δ Tmem119 and APP/PS1 groups.
Fig. 6 Microglial deficiency of SIRT2 modifies the transcriptome in the context of Alzheimer ' s disease pathology. (A) Venn diagram illustrating the comparison of differentially expressed genes between APP/PS1 versus Control microglia and APP/PS1-SIRT2 Δ Tmem119 versus SIRT2 Δ Tmem119 microglia. Overlapping areas represent shared genes between the two comparisons, while non-overlapping regions indicate genes specific to each group. (B) Heatmap of the Gene Ontology (GO) functional analysis of differentially expressed genes in the comparisons APP/PS1 versus Control microglia and APP/PS1 versus APP/PS1-SIRT2 Δ Tmem119 microglia. Color intensity represents the statistical significance ( log10 p-value) of each enriched GO term. (C) Top 20 GO Biological Processes altered in the comparison between APP/PS1-SIRT2 Δ Tmem119 and APP/PS1 groups.CC-BY · From the PDF
Image 8
CC-BY · From the PDF
Fig. 7 Microglial deficiency of SIRT2 impairs neuronal activity and alters spine morphology. (A) Quantification of c-Fos positive cells (left) and representative c-Fos staining (green) in the dentate gyrus of the hippocampus (right) (n = 5 -6 mice per group). Scale bar = 300 µ m. (B) Representative hippocampal sections of NeuN staining (red; left) and quantitative measurement of NeuN expression in the hippocampus (right) (n = 5 mice per group). Scale bar = 200 µ m. (C) Spine density. (D) Percentage of thin (F = 4.819, *p < 0.05, two-way ANOVA followed by Tukey ' s test) and (E) mushroom type spines (F = 6.765, *p < 0.05, two-way ANOVA followed by Tukey ' s test) (n = 5 animals per group). (F) Representative images of Golgi-Cox-stained dendritic spines. Scale bar = 1 µ m. (G) (Left) Time course of mean fEPSP slope in hippocampal slices from control, SIRT2 Δ Tmem119 , APP/PS1 and APP/PS1-SIRT2 Δ Tmem119 mice in basal conditions and following induction of theta burst stimulation at 10 min (arrow). (Right) Average relative changes of fEPSP slopes in hippocampal mice slices before (basal) and after 60 min (LTP) application of theta burst (F = 4.512, *p < 0.05, one-way ANOVA followed by Tukey ' s test) (n = 3 -5 animals per group, 3 -4 slices per animal). Results are shown as mean ± SEM. a.u.: arbitrary units.
Fig. 7 Microglial deficiency of SIRT2 impairs neuronal activity and alters spine morphology. (A) Quantification of c-Fos positive cells (left) and representative c-Fos staining (green) in the dentate gyrus of the hippocampus (right) (n = 5 -6 mice per group). Scale bar = 300 µ m. (B) Representative hippocampal sections of NeuN staining (red; left) and quantitative measurement of NeuN expression in the hippocampus (right) (n = 5 mice per group). Scale bar = 200 µ m. (C) Spine density. (D) Percentage of thin (F = 4.819, *p < 0.05, two-way ANOVA followed by Tukey ' s test) and (E) mushroom type spines (F = 6.765, *p < 0.05, two-way ANOVA followed by Tukey ' s test) (n = 5 animals per group). (F) Representative images of Golgi-Cox-stained dendritic spines. Scale bar = 1 µ m. (G) (Left) Time course of mean fEPSP slope in hippocampal slices from control, SIRT2 Δ Tmem119 , APP/PS1 and APP/PS1-SIRT2 Δ Tmem119 mice in basal conditions and following induction of theta burst stimulation at 10 min (arrow). (Right) Average relative changes of fEPSP slopes in hippocampal mice slices before (basal) and after 60 min (LTP) application of theta burst (F = 4.512, *p < 0.05, one-way ANOVA followed by Tukey ' s test) (n = 3 -5 animals per group, 3 -4 slices per animal). Results are shown as mean ± SEM. a.u.: arbitrary units.CC-BY · From the PDF
Image 10
CC-BY · From the PDF

Verification

Claims the paper makes

0 Valid · 0 Not valid · 46 Not checked · 154 Own results and interpretations

126 more claims

Create a free account to see all 200 claims and to verify the 70 references still open.

See all claims — free account
  • It may state two separate claims as one. 37
  • Probably not a substantial claim. 39
  • The quote only partly states this claim. 4

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 94 references

Cited by

Metadata

Authors
Sola-Sevilla, N., Garmendia-Berges, M., Aleixo, M., Mera-Delgado, M., Solas, M., Tordera, R. M., García-Carracedo, L., Expósito, S., Anaya-Cubero, E., Fernández-Irigoyen, J., Guruceaga, E., Santamaria, E., Martin, E. D., & Puerta, E.
Affiliations
  • Navarre Institute of Health Research (ES)
  • Consejo Superior de Investigaciones Científicas (ES)
Corresponding author
Puerta, Elena
Venue
Brain, Behavior, and Immunity
Publisher
Elsevier BV
Published
2025-10
Volume
129
Pages
223-243
ISSN
0889-1591 (ISSN-L)
OpenAlex
W4411147880
Cited by
5
References
96
Citations by year
2026: 3 · 2025: 2
FWCI
1.35
Type
journal article
Language
en
Open access
Licence
Locations
  • Brain Behavior and Immunity (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (submittedVersion)
  • Academica-e (Universidad Pública de Navarra) (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DIGITAL.CSIC (Spanish National Research Council (CSIC)) (publishedVersion, other-oa)
Funders
  • Ministerio de Ciencia, Innovación y Universidades (PID2020, .13039/501100011033, 501100011033)
  • Universidad de Navarra
  • Agencia Estatal de Investigación (501100011033, 13039, .13039/501100011033)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
Keywords
SIRT2, microglia, Alzheimer's disease, cognitive decline, amyloid plaques, conditional knockout mice, APP/PS1 mice, inflammatory cytokines, synaptic dysfunction, long-term potentiation, aging
MeSH terms
Alzheimer Disease, Animals, Brain, Disease Models, Animal, Male, Amyloid beta-Peptides, Microglia, Mice, Knockout, Mice, Sirtuin 2, Plaque, Amyloid, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-19, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-19 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.